Impact of Emerging Technologies on Regulatory Science

Rashid Almulla^*
*Correspondence: Rashid Almulla, Department Computer Science, Kuwait University, Kuwait city, Kuwait, Email:

Introduction

The novel techniques and emerging cellular, molecular, and in silico technologies is becoming more and more important for determining the safety of foods, medicines, and personal care items. These new technologies' convergence is also permitting quick advancements and methods that could affect regulatory judgements and approvals. There is worry that these new technologies have not been adequately assessed to see whether they are ready for regulatory use, either individually or in combination, even though the development of emerging technologies may allow rapid advancements in regulatory decision-making. The scale of these combined technical advancements may be more than what can be done to determine whether these new approaches are fit for purpose and to allow routine application of them for regulatory purposes. Utilizing novel techniques and emerging cellular, molecular, and Insilco technologies is becoming more and more important for determining the safety of foods, medicines, and personal care items. These new technologies' convergence is also permitting quick advancements and methods that could affect regulatory judgements and approvals. Although mechanisms for assessing new technologies to decide which ones are suitable for use in regulations must be developed. It is nevertheless a priority to provide the option for these possibly quicker, more accurate and economical technologies to be used in regulatory applications. However, the value of these efforts could not be realised right once or might take longer if there is no clear plan in place to analyse developing technologies quickly and effectively. It is critical for the discipline of regulatory science to stay current with research in these highly technical areas and to comprehend the science underlying these novel approaches. To prepare workforces for upcoming global regulatory issues, the regulatory sector must comprehend the essential qualities of these creative approaches and learn from one another's experiences. In order to build a plan for the evaluation of these new and innovative assessment tools, it is crucial that the regulatory community collaborate with the technology developers. There is worry that these new technologies have not been fully assessed to see whether they are ready for regulatory application, either alone or in combination. The development of emerging technologies may allow quick advancements in regulatory decision making. The scale of these combined technical advancements may be more than what can be done to determine whether these new approaches are fit for purpose and to allow routine application of them for regulatory purposes.

Discussion

Future regulatory science will be significantly influenced by emerging technology. One may contend that new methods have been used and included into the safety assessment process over its entire history. It is obvious that an evaluation of the readiness for these new techniques to be implemented into the assessment process is required as the rate of creation of novel approaches quickens [1]. Clear examples of how to evaluate the reproducibility, reliability, and robustness of these new technologies have been revealed by looking at the fields of artificial intelligence (AI) and machine learning (ML), omics, biomarkers, and precision medicine, microphysiological systems and stem cells, bioimaging, and the microbiome. There is a call for academic researchers, product developers, and regulators to collaborate on developing techniques to confirm the effectiveness of these novel approaches to anticipate impact on human health [2].

An elite group of authors from around the world were carefully chosen by the Global Summit on Regulatory Science (GSRS20) organising committee to discuss the topic of Emerging Technologies and Their Impact on Regulatory Science. There is concern that these new technologies have not been adequately assessed to see whether they are ready for regulatory use, even though the emergence of emerging technologies may allow quick advancements in regulatory decision-making. Determining whether an alternative strategy is prepared for everyday usage in the regulatory context may be difficult given the quantity and diversity of these alternatives [3]. It is necessary to establish methods for assessing the new technologies' dependability, repeatability, and robustness when used in regulatory decision-making. To ascertain whether the new methods are prepared for regulatory usage, it is necessary to analyse them. These methods may be quicker, more accurate, and more economical. To quickly and appropriately assess emerging technologies, a clear plan must be devised [4]. Additionally, regulatory scientists must use the novel methodologies to comprehend their advantages and disadvantages. For these cutting-edge methods, the regulatory community must establish acceptable quality criteria and disseminate this knowledge to others in the regulatory science community [5]. It is crucial that the regulatory community collaborate with technology developers to maximise the potential of the new technology and create a plan for assessing these cutting-edge assessment techniques.

The GSRS20's carefully chosen writers give readers a thorough knowledge of the extent and state of current efforts to use emerging technology to regulatory science. To address the promise of emerging technologies and their application to regulatory science, the GSRS20 organising committee, under the direction of the Global Coalition for Regulatory Science Research (GCRSR), brought together an exceptional group of international science thinking leaders [6].

Conclusion

The previous summaries make it clear that regulatory science will be greatly impacted by developing technologies in the future. One may contend that new methods have been used and included into the safety assessment process over its entire history. It is obvious that an evaluation of the readiness for these new techniques to be implemented into the assessment process is required as the rate of creation of novel approaches quickens. Clear examples of how to evaluate the repeatability, dependability, and robustness of these new technologies have been disclosed by looking at the fields of AI and ML, Omics, Biomarkers, and Precision Medicine, Microphysiological Systems and Stem Cells, Bioimaging, and the Microbiome. There is a call for product developers, regulators, and academic researchers to collaborate on developing techniques to confirm the effectiveness of these novel approaches to forecast influence on human health in a group movement. When that happens, new technologies that consistently and dependably produce reliable data for safety evaluations in comparison to current practises and reflecting the consequences on human health will be introduced into accepted testing regimes.

References

1. Allan, Jacqueline, Susanne Belz, Arnd Hoeveler and Hubert Rauscher, et al. "Regulatory landscape of nanotechnology and nanoplastics from a global perspective." Regul Toxicol Pharmacol 122 (2021): 104885.

Google Scholar, Crossref, Indexed at

2. Honma, Masamitsu. "An assessment of mutagenicity of chemical substances by (quantitative) structure–activity relationship." Genes Environ 42 (2020): 1-13.

Google Scholar, Crossref, Indexed at

3. Yamamoto, Eiichi, Yuhji Taquahashi, Makiko Kuwagata and Futoshi Sato, et al. "Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-μm aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging." Int J Pharm 595 (2021): 120241.

Google Scholar, Crossref, Indexed at

4. Anklam, Elke, Martin Iain Bahl, Robert Ball and Philippe Girard, et al. "Emerging technologies and their impact on regulatory science." Exp Biol Med 247 (2022): 1-75.

Google Scholar, Crossref, Indexed at

5. Lambert, Dominic, Arthur Pightling, Emma Griffiths and Duncan Craig, et al. "Baseline practices for the application of genomic data supporting regulatory food safety." J AOAC Int 100 (2017): 721-731.

Google Scholar, Crossref, Indexed at

6. Blais, Burton W, Kyle Tapp, Martine Dixon and Catherine D. Carrillo. "Genomically Informed Strain-Specific Recovery of Shiga Toxin–Producing Escherichia coli during Foodborne Illness Outbreak Investigations." J Food Prot 82 (2019): 39-44.

Google Scholar, Crossref, Indexed at